Cancer occurred in 18% of patients with CTEPH, and mortality rates were higher among those with cancer vs those without (28% vs 6%). Patients with chronic thromboembolic pulmonary hypertension (CTEPH) ...
The EMA approved Adempas four months after Opsumit but for two indications- PAH and chronic thrombo-embolic pulmonary hypertension (CTEPH). However, the EMA estimated only a minor increase in the ...